Cargando…

Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case

[F-18]-AV-1451 is a novel positron emission tomography (PET) tracer with high affinity to neurofibrillary tau pathology in Alzheimer’s disease (AD). PET studies have shown increased tracer retention in patients clinically diagnosed with dementia of AD type and mild cognitive impairment in regions th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marquié, Marta, Verwer, Eline E., Meltzer, Avery C., Kim, Sally Ji Who, Agüero, Cinthya, Gonzalez, Jose, Makaretz, Sara J., Siao Tick Chong, Michael, Ramanan, Prianca, Amaral, Ana C., Normandin, Marc D., Vanderburg, Charles R., Gomperts, Stephen N., Johnson, Keith A., Frosch, Matthew P., Gómez-Isla, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648451/ https://www.ncbi.nlm.nih.gov/pubmed/29047416 http://dx.doi.org/10.1186/s40478-017-0482-0

Ejemplares similares

[(18)F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series
por: Marquié, Marta, et al.
Publicado: (2019)

An autoradiographic evaluation of AV-1451 Tau PET in dementia
por: Lowe, Val J., et al.
Publicado: (2016)

In vivo retention of (18)F-AV-1451 in corticobasal syndrome
por: Smith, Ruben, et al.
Publicado: (2017)

Increased Uptake of AV-1451 in a Subacute Infarction Lesion
por: Cho, Soo Hyun, et al.
Publicado: (2018)

Quantification of Tau Load Using [(18)F]AV1451 PET
por: Golla, Sandeep S. V., et al.
Publicado: (2017)

An updated radiosynthesis of [(18)F]AV1451 for tau PET imaging
por: Mossine, Andrew V., et al.
Publicado: (2017)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

(18)F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
por: Smith, Ruben, et al.
Publicado: (2018)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Imaging Aβ and tau in early stage Alzheimer’s disease with [(18)F]AV45 and [(18)F]AV1451
por: Firouzian, Azadeh, et al.
Publicado: (2018)

[(18)F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
por: Bevan Jones, W. Richard, et al.
Publicado: (2016)

AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2016)

Considerations and code for partial volume correcting [(18)F]-AV-1451 tau PET data
por: Baker, Suzanne L., et al.
Publicado: (2017)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

Increased basal ganglia binding of (18) F‐AV‐1451 in patients with progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

(18)F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy
por: Passamonti, Luca, et al.
Publicado: (2017)

(18)F-AV1451 PET imaging and multimodal MRI changes in progressive supranuclear palsy
por: Nicastro, Nicolas, et al.
Publicado: (2019)

Increased retention of tau PET ligand [(18)F]-AV1451 in Alzheimer’s Disease Psychosis
por: Gomar, J. J., et al.
Publicado: (2022)

Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue
por: Aguero, Cinthya, et al.
Publicado: (2019)

(18)F‐AV‐1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy
por: Nedelska, Zuzana, et al.
Publicado: (2019)

[(18)F]-AV-1451 binding in the substantia nigra as a marker of neuromelanin in Lewy body diseases
por: Mak, Elijah, et al.
Publicado: (2021)

Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography
por: Li, Yuan, et al.
Publicado: (2019)

(18)F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
por: Smith, Ruben, et al.
Publicado: (2016)

[(18)F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion
por: Bevan‐Jones, Richard W., et al.
Publicado: (2018)

Imaging tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography
por: Mak, Elijah, et al.
Publicado: (2021)

Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer’s Tauopathy
por: Murugan, N. Arul, et al.
Publicado: (2021)

Binding of [(18)F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients
por: Schaeverbeke, Jolien, et al.
Publicado: (2019)

Cerebral [(18) F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy
por: Dickstein, D L, et al.
Publicado: (2016)

MAPT rs242557 variant is associated with hippocampus tau uptake on (18)F-AV-1451 PET in non-demented elders
por: Shen, Xue-Ning, et al.
Publicado: (2019)

Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [(18)F]-AV-1451 PET data
por: Young, Christina B., et al.
Publicado: (2021)

Molecular pathology and synaptic loss in primary tauopathies: an (18)F-AV-1451 and (11)C-UCB-J PET study
por: Holland, Negin, et al.
Publicado: (2021)

Deep learning application for the classification of Alzheimer’s disease using (18)F-flortaucipir (AV-1451) tau positron emission tomography
por: Park, Sang Won, et al.
Publicado: (2023)

[(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia
por: Bevan-Jones, W R, et al.
Publicado: (2018)

Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation
por: Amaral, Ana Claudia, et al.
Publicado: (2021)

Collaboration Agreement K1451
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2008)

University of Glasgow—1451-1951
Publicado: (1951)

Quantitative (18)F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients
por: Zhao, Qian, et al.
Publicado: (2019)

Sex modulates the ApoE ε4 effect on brain tau deposition measured by (18)F-AV-1451 PET in individuals with mild cognitive impairment
por: Liu, Min, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ubijl2jgc6b1aq3fmdl67mpges